{"prompt": "['In study BH29884, the ABR was 2.9 events (95% CI, 1.7 to 5.0) among participants who were', 'randomly assigned to emicizumab prophylaxis (Group A, 35 participants) versus 23.3 events (95%', 'CI, 12.3 to 43.9) among those assigned to no prophylaxis (Group B, 18 participants), representing a', 'significant difference of 87% in favor of emicizumab prophylaxis (p<0.001). A total of 22 participants', 'in Group A (63%) had zero bleeding events, as compared with 1 participant (6%) in Group B.', 'Among 24 participants in Group C who had participated in a NIS, emicizumab prophylaxis resulted', 'in a bleeding rate that was significantly lower by 79% than the rate with previous bypassing-agent', 'prophylaxis (p<0.001) (Oldenburg et al. 2017).', 'The exposure-response relationship for emicizumab was quantitatively characterized and', 'simulations suggested that the trough concentration of emicizumab needed for almost', 'complete inhibition of bleeding onset is 45 g/mL. On the basis of population PK modeling,', 'a median trough plasma concentration of 45 g/mL is predicted to be achieved after', 'treatment with 4 weekly doses of 3 mg/kg and maintained, thereafter, with weekly doses of', '1.5 mg/kg. In light of this finding, the loading dose of 3 mg/kg emicizumab per week for 4', 'weeks was chosen in order to rapidly achieve the effective trough concentration of 45 g/mL', 'without exceeding the maximum dose of 3 mg/kg weekly investigated in the Phase I/II', 'studies. Thereafter, a dose and schedule of 1.5 mg/kg weekly was chosen in order to reduce', 'the peak-trough fluctuations and to maintain emicizumab plasma concentrations above', '45 g/mL over the entire dosing interval. This dosing regimen (i.e., 3 mg/kg weekly for', '4 weeks followed by 1.5 mg/kg weekly) will, therefore, be investigated in this study.', 'A study duration of approximately 2 years for each individual patient has been chosen in', 'order to thoroughly assess the long-term safety of prophylactic use of emicizumab.', '3.3.2', 'Rationale for Patient Population', 'Patients with congenital hemophilia A who have persistent inhibitors against FVIII at enrollment', 'will comprise the primary population for this Phase Illb study investigating the safety,', 'tolerability, efficacy, immunogenicity, and PK of prophylactic administration of emicizumab.', 'Patients may have received episodic or prophylactic treatment before enrollment; at least', 'one documented treatment with bypassing agents or FVIII concentrates is required within', 'the last 6 months to indicate the need for prophylactic emicizumab treatment.', 'Based on current treatment algorithms for patients with hemophilia A with inhibitors', '(Kempton and White Il 2009; Srivastava et al. 2013), it is anticipated that the majority of', 'adults and adolescents treated with emicizumab will have previously undergone ITI without', 'success or are not candidates for ITI. As clinical safety data relating to the concomitant use', 'of prophylactic emicizumab during ITI are not available at this time, patients currently', 'receiving ITI will not be eligible for this study. Patients receiving ITI therapy will be eligible', 'following the completion of a 72-hour washout period prior to the first emicizumab administration.', 'Owing to the fact that the presence or amount of FVIII inhibitors in their plasma does not', \"impact the efficacy of emicizumab, patients' inhibitor titers at the time of study entry will not\", 'influence their study eligibility.', 'Emicizumab - F. Hoffmann-La Roche Ltd', '105 / Protocol MO39129, Version 3']['3.3.3', 'Rationale for Control Group', 'This study involves the use of a single-arm study design and therefore a control group will', 'not be used. The primary endpoint of this study is to evaluate the overall safety and', 'tolerability of prophylactic administration of emicizumab in patients with congenital hemophilia', 'A who have persistent inhibitors against FVIII. As hemophilia A is a rare disease (Acharya 2013)', 'and the study is designed to investigate the broad safety profile of emicizumab,', 'approximately 200 patients will be enrolled. Given the size of the patient population, a single-', 'arm study design without a control group is considered an appropriate method to capture the', 'safety data that will be observed following the use of emicizumab. This type of study design', 'has been used extensively in previous clinical studies involving patients with rare diseases', '(Bell and Tudur Smith 2014).', '3.3.4', 'Rationale for Biomarker Assessments', 'The identity of effective PD, safety, and bone and joint biomarkers has not been fully', 'elucidated and further testing is required to determine which assays and technical conditions', 'are most suitable for use with emicizumab treatment. Plasma and serum samples will be', 'collected for PD, safety, and bone and joint biomarker assessments at specific clinic visits in', 'order to obtain evidence of the biologic activity of emicizumab in patients (see Appendix 2', 'Schedule of Biomarker Samples', ').', 'The PD biomarkers include, but are not limited to, coagulation assays such as aPTT and', 'FVIII activity assays. The results of the Phase I/II study have shown that a dose-response', 'relationship was apparent between aPTT and emicizumab concentration (for more', \"information, see the Investigator's Brochure). The aPTT assay will be run in a modified form\", 'to ensure that the assay range covers all levels of emicizumab exposure. In addition, clot', 'waveform analysis (CWA) may be run as an exploratory PD coagulation assay.', 'The safety biomarkers will be used to monitor patient safety throughout the study and may', 'include, but are not limited to, D-dimer.', 'Exploratory safety coagulation system biomarkers will include Factor VIII antigen (FVIII:Ag),', 'Factor IX antigen (FIX:Ag), and Factor X antigen (FX:Ag) to assess whether drug treatment', 'causes alterations in the circulating levels of the coagulation factors that are the binding', 'targets for emicizumab. Measurement of other coagulation or hemophilia-related factors may', 'also be conducted.', 'The bone and joint biomarkers will include exploratory biomarkers of bone turnover and joint', 'health. The selection of bone and joint biomarkers that will be tested will be based on', 'findings from biomarker analyses in other emicizumab trials (see Appendix 2', 'Schedule of Biomarker Samples', ').', 'Residual blood and/or, plasma, and serum from collected biomarker samples may be stored', 'for up to 5 years after the final Clinical Study Report has been completed and may be used for', 'additional exploratory emicizumab-related research, to guide development of potential in', 'Emicizumab - F. Hoffmann-La Roche Ltd', '106 / Protocol MO39129, Version 3']\n\n###\n\n", "completion": "END"}